Italia markets open in 1 hour 19 minutes

Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
73,65-0,87 (-1,17%)
Alla chiusura: 04:00PM EST
73,65 0,00 (0,00%)
Dopo ore: 07:57PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente74,52
Aperto74,31
Denaro0,00 x 1200
Lettera0,00 x 1100
Min-Max giorno72,94 - 74,42
Intervallo di 52 settimane65,82 - 81,44
Volume9.043.949
Media Volume9.030.098
Capitalizzazione156,592B
Beta (5 anni mensile)0,42
Rapporto PE (ttm)24,97
EPS (ttm)2,95
Prossima data utili27 apr 2023
Rendimento e dividendo (forward)2,28 (3,06%)
Data ex dividendo05 gen 2023
Stima target 1A82,44
  • GlobeNewswire

    iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors

    LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of

  • GlobeNewswire

    Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million

    – $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura’s cash runway into 2026, if term loan is fully drawn – SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced a $25 million equity investment from Brist

  • GlobeNewswire

    Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System

    - Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option exercise fees and development milestone payments plus royalties - LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into an agreement with Bristol M